Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

NCT00550004 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: RP101
DRUG: Gemcitabine (1000 mg/m2)

Sponsor

SciClone Pharmaceuticals